Skip to main content
SpringerLink
Log in

Ablehnung beruht auf „alten“ Betablockern

Moderne vasoaktive Substanzen bevorzugt einsetzen

  • Schwerpunkt_Pro & Kontra
  • Published:
CardioVasc Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur pro Betablocker

  1. James PA, Oparil S, Carter BL et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–20

    Article  CAS  PubMed  Google Scholar 

  2. Weber MA, Schiffrin EL, White WB et al. Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014;32(1):3–15

    Article  CAS  PubMed  Google Scholar 

  3. National Institute for Health and Care Excellence. Hypertension: Clinical management of primary hypertension in adults. NICE clinical guideline 127. Issued August 2011. www.nice.org.uk/guidance/CG127

  4. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357

    Article  CAS  PubMed  Google Scholar 

  5. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366(9496):1545–53

    Article  CAS  PubMed  Google Scholar 

  6. M. Middeke, Mr. Noed Study Group. Blood Pressure and Heart Rate in Hypertensives under Nebivolol and Metoprolol — a double blind cross over study. 23rd scientific meeting of the European Society of Hypertension (ESH), Milan 2013, Poster LB14

  7. Van Nueten L, Schelling A, Vertommen C et al. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11:813–19

    Article  CAS  PubMed  Google Scholar 

  8. Van Nueten L, Lacourcière Y, Vyssoulis et al. Nebivolol Versus Nifedipine in the Treatment of Essential Hypertension: A Double-Blind, Randomized, Comparative Trial. Am J Therapeutics. 1998;5:237–43

    Article  CAS  Google Scholar 

  9. Predel HG, Mainka W, Schillings W et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens. 2001;15(10):715–21

    Article  CAS  PubMed  Google Scholar 

  10. Van Bortel LM, van Baak MA. Exercise tolerance with nebivolol and atenolol. Cardiovasc Drugs Ther. 1992;6(3):239–47

    Article  CAS  PubMed  Google Scholar 

  11. Pischon T, Sharma AM, Mansmann U, Agrawal R. Effect of Forced Titration of Nebivolol on Response Rate in Obese Hypertensive Patients. Am J Hypertens. 2003;16:98–100

    Article  PubMed  Google Scholar 

  12. Poirier L, Cléroux J, Nadeau A, Lacourcière Y. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens. 2001;19:1429–35

    Article  CAS  PubMed  Google Scholar 

  13. Brixius K, Middeke M, Lichtenthal A et al.Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34(4):327–31

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertoniezentrum München, Excellence Centre of the European Society of Hypertension (ESH), Herzzentrum Alter Hof, Dienerstr. 12, 80331, München, Deutschland

    Martin Middeke

Authors
  1. Martin Middeke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Middeke, M. Moderne vasoaktive Substanzen bevorzugt einsetzen. CV 15, 40 (2015). https://doi.org/10.1007/s15027-015-0569-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-015-0569-0

Search

Navigation